Skip to main
AXGN
AXGN logo

AxoGen (AXGN) Stock Forecast & Price Target

AxoGen (AXGN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Axogen Inc. has demonstrated strong business growth, evidenced by a 13.6% compound annual growth rate (CAGR) in revenue since 2020, alongside a notable increase in active breast resensation programs and surgeon participation, which rose by 7% and 20% year-over-year, respectively. The reimbursement landscape for allograft procedures has also significantly improved, with ambulatory surgery center reimbursements surging 138% since 2019, reflecting the growing acceptance and economic viability of Axogen's products. Additionally, the company is expected to achieve sustainable profitability by 2026, fueled by the expanding market penetration of its nerve repair technologies in various surgical applications.

Bears say

Axogen Inc faces significant challenges that contribute to a negative outlook, including lower-than-projected sales growth stemming from competitive pressures and regulatory concerns, particularly with the ongoing uncertainty around the FDA submission for Avance. The company's historical net losses and reliance on a limited number of products heighten risks related to customer acquisition and market penetration, while potential issues with scaling operations and supply chain management could further hinder revenue growth. Additionally, the reliance on key management, acceptance within the medical community, and risks of infringement on third-party intellectual property present a complex landscape that limits Axogen's ability to achieve sustainable profitability.

AxoGen (AXGN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AxoGen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AxoGen (AXGN) Forecast

Analysts have given AxoGen (AXGN) a Buy based on their latest research and market trends.

According to 7 analysts, AxoGen (AXGN) has a Buy consensus rating as of Nov 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AxoGen (AXGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.